Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
6.33
-0.18 (-2.76%)
At close: Oct 23, 2026, 4:00 PM EDT
6.30
-0.03 (-0.40%)
After-hours: Oct 23, 2026, 7:52 PM EDT
Agenus Revenue
Agenus had revenue of $34.52M in the quarter ending June 30, 2026, with 34.36% growth. This brings the company's total for the last twelve months to $132.69M, up 30.47% year-over-year. In the year 2025, Agenus had annual revenue of $114.20M with 10.37% growth. That makes Agenus the 20,539th largest company in the world by revenue and 3,115th in the United States.
Revenue (ttm)
$132.69M
Revenue Growth
+30.47%
P/S Ratio
2.15
Revenue / Employee
$1,638,185
Employees
81
Market Cap
284.98M
Revenue by Geography
- United States 113.16M 99.1%
- Rest of World 1.04M 0.9%
Fiscal year ended Dec 31, 2025 See the full Agenus breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 114.20M | 10.73M | 10.37% |
| Dec 31, 2024 | 103.46M | -52.85M | -33.81% |
| Dec 31, 2023 | 156.31M | 58.29M | 59.47% |
| Dec 31, 2022 | 98.02M | -197.64M | -66.85% |
| Dec 31, 2021 | 295.67M | 207.50M | 235.34% |
| Dec 31, 2020 | 88.17M | -61.88M | -41.24% |
| Dec 31, 2019 | 150.05M | 113.26M | 307.92% |
| Dec 31, 2018 | 36.78M | -6.09M | -14.21% |
| Dec 31, 2017 | 42.88M | 20.30M | 89.95% |
| Dec 31, 2016 | 22.57M | -2.24M | -9.04% |
| Dec 31, 2015 | 24.82M | 17.84M | 255.67% |
| Dec 31, 2014 | 6.98M | 3.93M | 129.13% |
| Dec 31, 2013 | 3.05M | -12.92M | -80.92% |
| Dec 31, 2012 | 15.96M | 13.20M | 479.17% |
| Dec 31, 2011 | 2.76M | -603.84K | -17.97% |
| Dec 31, 2010 | 3.36M | 25.17K | 0.75% |
| Dec 31, 2009 | 3.33M | 683.36K | 25.78% |
| Dec 31, 2008 | 2.65M | -2.90M | -52.25% |
| Dec 31, 2007 | 5.55M | 4.86M | 702.20% |
| Dec 31, 2006 | 692.14K | 62.16K | 9.87% |
| Dec 31, 2005 | 629.98K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Century Therapeutics | 109.16M |
| Fulcrum Therapeutics | 80.00M |
| Arcturus Therapeutics Holdings | 29.37M |
| X4 Pharmaceuticals | 15.85M |
| Alector | 13.86M |
| Surrozen | 11.51M |
| Ocugen | 4.58M |
| Inhibikase Therapeutics | 1.00 |
AGEN News
- 1 day ago - Agenus to Provide Third Quarter 2026 Financial Report and Development Update - Business Wire
- 3 days ago - Agenus Transcript: Chardan's 10th Annual Healthcare Conference - Transcripts
- 14 days ago - Agenus to Participate in Chardan's 10th Annual Healthcare Investor Conference - Business Wire
- 15 days ago - Agenus announces Armenia granted marketing authorizations for BOT+BAL - TheFly
- 15 days ago - Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer - Business Wire
- 19 days ago - Agenus announces 3-year follow-up results from Phase 1b C-800-01 trial - TheFly
- 20 days ago - Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - Business Wire
- 21 days ago - Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026 - Business Wire